Global Brain-Computer Interface Companies Reach 1,175 As China Concentrates Nearly 80 Percent In Three Major Clusters

6 Min Read
Global Brain-Computer Interface Companies Reach 1,175 As China Concentrates Nearly 80 Percent In Three Major Clusters

Global Growth and Cluster Concentration

Brain-computer interface technology allows direct communication pathways between a wired or wireless brain and external devices. Global brain-computer interface companies have grown from more than 800 to 1,175, according to the 2026 Brain-Computer Interface (BCI) Industry In-Depth Report published by C. Barnes and Company and Shanghai Jiao Tong University. The 2026 Brain-Computer Interface Conference took place from November 21 to 22 in Changping, Beijing, hosted by the China Academy of Information and Communications Technology under the theme of connecting brain, intelligence, and chips. At the main forum, the Brain-Computer Interface Industry Alliance released the 2026 Brain-Computer Interface Innovation Development Research Report, revealing that Chinese related companies are highly concentrated in the three major city clusters of Beijing-Tianjin-Hebei, the Yangtze River Delta, and Guangdong-Hong Kong-Macao. These clusters total more than 190 enterprises and account for 77.4 percent of the national total.

Contents
  1. Global Growth and Cluster Concentration
  2. Market Size and Global Competitive Landscape
  3. Technology Routes and Generational Evolution
  4. Clinical Trials and Technological Milestones
  5. Capital Markets and Policy Empowerment
  6. Industry Integration and Future Outlook
  7. The Essentials

The top five provinces and municipalities for these enterprises in China are Guangdong province, Beijing, Shanghai, Jiangsu province, and Zhejiang province. Industry concentration is now approaching that of the biopharmaceutical sector, which means businesses cluster closely together near specialized talent, research facilities, and funding sources. Most newly added companies worldwide have chosen pathways with lower technical thresholds and faster industrialization to speed up product validation and market entry. While this orientation helps businesses test products quickly, it also means that pressure from homogeneous competition, where many companies sell nearly identical items, is building up across the market.

Market Size and Global Competitive Landscape

The global market size for brain-computer interface technology is projected to grow from USD 2.14 billion in 2024 to USD 12.4 billion in 2034. In domestic markets, China is expected to see its market size grow from RMB 1.73 billion in 2023 to RMB 3.89 billion in 2027. The global competitive landscape shows a dual-core dynamic led by the United States and China, which together account for over half of global market share and core enterprise resources. American enterprises represent 34 percent of global brain-computer interface companies, while Chinese enterprises account for 22 percent.

Looking at the entire industry chain, the sector features a dumbbell-shaped structure where upstream core components and downstream applications have many participants, while the midstream is narrower. Upstream core component enterprises account for 10 percent of the total, midstream system integrators and software algorithm developers account for 20 percent, and downstream application enterprises make up 70 percent. Current market revenue mainly comes from two primary fields, which are scientific research and medical applications.

Advertisement

Technology Routes and Generational Evolution

Technology choices in this industry involve balancing signal quality, invasion risk, and usage thresholds. Non-invasive technology, which relies on sensors placed outside the scalp without surgery, currently accounts for 82 percent of the Chinese market due to its lower barrier to entry. Among downstream application enterprises, medical applications account for 56 percent, while non-medical applications such as consumer electronics and industrial safety account for 44 percent. Medical applications focus heavily on neurological rehabilitation and functional substitution for patients with motor disabilities.

The research report categorizes brain-computer interfaces into four distinct generations based on telecommunications frameworks. The first generation consists of one-way devices for open-loop sensing and open-loop modulation, where reading brain signals and writing or stimulating signals are separated. The second generation, which serves as the current center of research and development, achieves closed-loop sensing and stimulation functions within the same target area. The third generation consists of multimodal brain-computer interfaces that integrate a cross-collaborative closed-loop ecosystem combining electricity, light, magnetism, and sound. The fourth generation points toward artificial intelligence-native and carbon-silicon integrated brain-computer interfaces.

Clinical Trials and Technological Milestones

Clinical trials serve as the primary bridge for moving technology from laboratory testing to commercial sales by verifying product safety and efficacy in humans. The number of annual clinical trials in China grew from 11 in 2023 to 31 in 2024, and reached 18 in the first half of 2025. Globally, the field achieved major milestones between 2024 and 2025. Neuralink completed its first human implant and achieved over 10 global implants, while domestic Chinese enterprises such as NeuroSky and BrainDrive successively completed their first human implants and real-time Chinese language decoding breakthroughs.

During the Changping conference, organizers released 15 landmark achievements showcasing core technology breakthroughs and scenario demonstrations. These included the Beinao-1 intelligent brain-computer system, a non-invasive high-precision electroencephalogram acquisition and computing chip, and an implantable neurostimulator. The concurrent exhibition attracted more than 60 organizations displaying upstream and downstream components, including high-throughput flexible electrodes and closed-loop neuromodulation devices used across medical rehabilitation, education, smart homes, and industrial safety.

Advertisement

Capital Markets and Policy Empowerment

Financial markets have responded strongly to these technological steps forward, driven by government policies such as the inclusion of brain-computer interfaces as a future industry in the national five-year plan. The National Healthcare Security Administration has also established special charge items for related clinical procedures. Since early 2025, stock prices of listed companies in this sector have climbed significantly. Among them, Innovation Medical rose 170 percent, Healthway Medical rose 119 percent, and Xiangyu Medical rose 89 percent.

Despite rapid financing and capital injection, the research report cautions that payment systems and talent supply chains remain incomplete. Strategic patience, capital patience, and sustained policy support are still required. If shortcomings in specialized talent and insurance reimbursement mechanisms are not addressed alongside technological gains, the overall pace of commercialization could slow down.

Industry Integration and Future Outlook

Industry concentration is advancing alongside tighter governance and regulation, shifting the market away from generic products toward specialized depth and a clearer division of labor. All links across industry, academia, research, and application are extending from the middle toward both ends of the supply chain. For investors watching the sector, the report highlights two primary threads consisting of breakthrough technology directions like closed-loop modulation and multimodal integration, alongside upstream core component segments like specialized chips and electrodes.

The 77.4 percent concentration in three major Chinese city clusters helps shorten the path from laboratory bench to clinical bedside by leveraging local innovation ecosystems. However, this high concentration also raises concerns about uneven regional development across different provinces. As regulatory bodies refine rules and companies move closer to scaled product launches, the industry continues to transition from early scientific exploration toward structured commercial delivery.

Advertisement

The Essentials

  • Global brain-computer interface companies grew from over 800 to 1,175, with China concentrating 77.4 percent of its related companies in three major city clusters.
  • The global market size is projected to expand from USD 2.14 billion in 2024 to USD 12.4 billion in 2034, while China expects growth from RMB 1.73 billion in 2023 to RMB 3.89 billion in 2027.
  • Non-invasive technology accounts for 82 percent of the Chinese market, while medical applications make up 56 percent of downstream enterprise activities globally.
  • Annual clinical trials in China grew from 11 in 2023 to 31 in 2024, with another 18 recorded in the first half of 2025.
  • Stock prices for listed sector companies showed strong gains since early 2025, including a 170 percent increase for Innovation Medical.
Share This Article

You May also Like